Clinical and microbiological assessment of patients with a long-term diagnosis of human immunodeficiency virus infection and Candida oral colonization

Clinical Microbiology and Infection

Volumn 15, Issue 4, 2009, Pages 364-371

  Delgado, A C D ^a   de Jesus Pedro, R ^a   Aoki, F H ^a   Resende, M R ^a   Trabasso, P ^a   Colombo, A L ^b   de Oliveira, M S M ^a   Mikami, Y ^c   Moretti, M L ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c CHIBA UNIVERSITY   (Japan)

Author keywords

Antiretroviral therapy; Candida oral colonization; HIV patient

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; GENOMIC DNA; ITRACONAZOLE; KETOCONAZOLE; NYSTATIN; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDIASIS; CD4 LYMPHOCYTE COUNT; CLINICAL ASSESSMENT; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DOSE RESPONSE; FEMALE; FUNGAL COLONIZATION; FUNGAL STRAIN; FUNGUS ISOLATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PRIORITY JOURNAL; SALVAGE THERAPY; THRUSH;

CANDIDA; CANDIDA ALBICANS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 65449169652     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2009.02707.x     Document Type: Article

References (35)

1. Costa CR, Cohen AJ, Fernandes OFL et al. Asymptomatic oral carriage of Candida species in HIV-infected patients in the highly active antiretroviral therapy era. Rev Inst Med Trop Sao Paulo 2006; 48: 257-261.
2. Campisi G, Pizzo G, Milici ME et al. Candida carriage in the oral cavity of human immunodeficiency virus-infected subjects. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002; 93: 281-286.
3. Vargas KG, Joly S. Carriage frequency, intensity of carriage, and strains of oral yeast species vary in the progression to oral candidiasis in human immunodeficiency virus-positive individuals. J Clin Micobiol 2002; 40: 341-350.
4. Gottfredsson M, Cox GM, Indridason OS et al. Association of plasma levels of human immunodeficiency virus type 1 RNA and oropharyngeal candidiasis. J Infect Dis 1999; 80: 534-537.
5. Felix DH, Wray D. The prevalence of oral candidiasis in HIV-infected individuals and dental attainders in Edinburgh. J Oral Pathol Med 1993; 22: 418-420.
6. Migliorati CA, Birman EG, Cury AE. Oropharyngeal candidiasis in HIV-infected patients under treatment with protease inhibitors. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004; 98: 301-310.
7. Cauda R, Tacconelli E, Tumbarello M et al. Role of protease inhibitors in preventing recurrent oral candidosis in patients with HIV infection: a prospective case-control study. J Acquir Immune Defic Syndr 1999; 21: 20-25.
8. Erko G, Erturan Z. Oral Candida colonization of human immunodeficiency virus infected subjects in Turkey and its relation with viral load and CD4+ T-lymphocyte count. Mycoses 2007; 50: 485-490.
9. Pinjon E, Sullivan D, Salkin I et al. Simple, inexpensive, reliable method for differentiation of Candida dubliniensis from Candida albicans. J Clin Microbiol 1998; 36: 2093-2095.
10. Ellepola AN, Hurst SF, Elie CM et al. Rapid and unequivocal differentiation of Candida dubliniensis from other Candida species using species-specific DNA probes: Comparison with phenotypic identification methods. Oral Microbiol Immunol 2003; 83: 79-88.
11. Kurtzman CP, Robnett CJ. Identification of clinically important ascomycetous yeasts based on nucleotide divergence in the 5′end of the large-subunit (26S) ribosomal DNA gene. J Clin Microbiol 1997; 35: 1216-1233.
12. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard. CLSI document M27-A2. Wayne, PA: CLSI, 2002.
13. Branchini ML, Pfaller MA, Rhine-Chalberg J et al. Genotypic variation and slime production among blood and catheter isolates of Candida parapsilosis. J Clin Microbiol 1994; 32: 452-456.
14. Sanchez-Vargas LO, Ortiz-Lopez NG, Villar M et al. Point prevalence, microbiology ad antifungal susceptibility patterns of oral Candida isolates colonizing or infecting Mexican HIV/AIDS patients and healthy persons. Rev Iberoam Micol 2005; 22: 83-102.
15. Barchiesi F, Maracci M, Radi B et al. Point prevalence, microbiology and fluconazole susceptibility patterns of yeast isolates colonizing the oral cavities of HIV-infected patients in the era of highly active antiretroviral therapy. J Antimicrob Chemother 2000; 50: 999-1002.
16. Brawner DL, Cutler JM. Oral Candida albicans isolates from nonhospitalized normal carriers, immunocompetent hospitalized patients, and immunocompromised patients with or without acquired immunodeficiency syndrome. J Clin Microbiol 1989; 27: 1335-1341.
17. Korting HC, Ollert M, Georgii A et al. In vitro susceptibilities and biotypes of Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus. J Clin Microbiol 1988; 26: 2626-2631.
18. Pires MF, Birman EG, Costa CR et al. Candida albicans biotypes isolated from the oral cavity of HIV-positive patients. Rev Microbiol Sao Paulo 1996; 27: 46-50.
19. Melo NR, Taguchi H, Jorge J et al. Oral Candida flora from Brazilian human immunodeficiency virus infected patients in highly active antiretroviral therapy era. Mem Inst Oswaldo Cruz 2004; 99: 425-431.
20. Lupetti A, Guzzi G, Paladini A et al. Molecular typing of Candida albicans in oral candidiasis: Karyotype epidemiology with human immunodeficiency virus-seropositive patients in comparison with that with healthy carriers. J Clin Microbiol 1998; 33: 1238-1242.
21. Schmid J, Odds FC, Wiselka MJ et al. Genetic similarity and maintenance of Candida albicans strains from a group of AIDS patients, demonstrated by DNA fingerprinting. J Clin Microbiol 1992; 30: 935-941.
22. Masia Canuto MM, Gutierrez Rodero F, Ortiz de la Tabla Durcasse V et al. Epidemiology of yeast colonization and oropharyngeal infection other than Candida albicans in patients with HIV infection. Med Clin 1999; 112: 211-214.
23. Milan EP, de Laet Sant'Ana P, de Azevedo Melo AS et al. Multicenter prospective surveillance of oral Candida dubliniensis among adult Brazilian human immunodeficiency virus-positive and AIDS patients. Diagn Microbiol Infect Dis 2001; 41: 29-35.
24. Sant'Ana PL, Milan EP, Martinez R et al. Multicenter Brazilian study of oral Candida species isolated from AIDS patients. Mem Inst Oswaldo Cruz 2002; 97: 253-257.
25. Kirkpatrick WR, Revankar SG, Mctee RB et al. Detection of Candida dubliniensis in oropharyngeal samples from human immunodeficiency virus-infected patients in North America by primary CHROMagar Candida screening and susceptibility testing of isolates. J Clin Microbiol 1998; 36: 3007-3012.
26. Martinez M, López-Ribot JL, Kirkpatrick W et al. Replacement of Candida albicans with C. dubliniensis in human immunodeficiency virus-infected patients with oropharyngeal candidiasis treated with fluconazole. J Clin Microbiol 2002; 40: 3135-3139.
27. Diz Dios P, Ocampo A, Miralles C et al. Frequency of oropharyngeal candidiasis in HIV-infected patients on protease inhibitor therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999; 87: 437-441.
28. Tappuni AR, Fleming GJP. The effect of antiretroviral therapy on the prevalence of oral manifestation in HIV-infected patients: A UK study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001; 92: 623-628.
29. Patton LL, Hill C. Sensitivity, specificity and positive predictive value of oral opportunistic infections in adults with HIV/AIDS as markers of immune suppression and viral burden. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000; 90: 182-188.
30. Arribas JR, Hernandez-Albujar S, Gonzalez-Garcia JJ et al. Impact of protease inhibitor therapy on HIV-related oropharyngeal candidiasis. AIDS 2000; 14: 979-985.
31. Cauda R, Tacconelli E, Tumbarello M et al. Role of protease inhibitors in preventing recurrent oral candidosis in patients with HIV infection: a prospective case-control study. J Acquir Immune Defic Syndr 1999; 21: 20-25.
32. Gruber A, Speth C, Lukasser-Vogl E et al. Human immunodeficiency virus type 1 protease inhibitor attenuates Candida albicans virulence properties in vitro. Immunopharmacology 1999; 41: 227-234.
33. Hoegl L, Thoma-Greber E, Röcken M et al. HIV protease inhibitors influence the prevalence of oral candidosis in HIV-infected patients: results of a study over a period of 2 years. Mycoses 1998; 41: 321-325.
34. Veenstra J, van Praag RM, Krol A et al. Complications of varicella zoster virus reactivation in HIV-infected homosexual men. AIDS 1996; 10: 393-399.
35. Glesby MJ, Hoover DR, Tan T et al. Herpes zoster in women with and at risk for HIV: Data from the Women's Interagency HIV Study. J Acquir Immune Defic Syndr 2004; 37: 1604-1609.